阿比特龙联合多西他赛治疗转移性去势抵抗性前列腺癌患者的临床效果

Clinical analysis of abiraterone combined with docetaxel in patients with metastatic castration resistant prostate cancer

目的分析阿比特龙联合多西他赛治疗转移性去势抵抗性前列腺癌(mCRPC)的临床效果。方法选取2018年1月至2020年1月本院收治的90例mCRPC患者,将其随机分为观察组及对照组,每组45例。两组均在雄激素剥夺治疗的基础上进行治疗,其中对照组给予多西他赛化疗加用泼尼松,观察组给予阿比特龙联合多西他赛治疗并加用泼尼松。评估两组患者的治疗有效性、治疗前后的血清前列腺特异抗原(PSA)变化、生活质量评分、Karnofsky评分。结果对照组和观察组患者治疗后的有效率分别为60%(27/45)及80%(36/45),差异有统计学意义(χ^(2)=4.945,P=0.027)。与治疗前相比,两组患者治疗后的血清PSA水平显著降低(P<0.05),且治疗后观察组的PSA水平较对照组下降更明显(P<0.05)。观察组患者治疗后的生活质量评分及Karnofsky评分较对照组显著改善,差异均有统计学意义(均P<0.05)。结论阿比特龙联合多西他赛可以显著改善mCRPC患者的治疗效果,值得推广应用。

Objective To analyze the clinical effect of abiraterone acetate combined with docetaxel chemotherapy in the treatment of metaststic castration resistant prostate cancer(mCRPC).Methods From January 2018 to January 2020,90 patients with mCRPC treated in our hospital were randomly divided into observation group and control group,45 cases in each group.Both groups were treated on the basis of androgen deprivation.The control group was treated with docetaxel and prednisone,while the observation group was treated with abiterone combined with docetaxel and prednisone.The treatment effects,PSA changes before and after treatment,quality of life scores,and Karnofsky scores were compared between the two groups,and the adverse reactions during the treatment were observed.Results The effective rates of the two groups after treatment were 60%(27/45)and 80%(36/45)respectively,and the differences between the groups were statistically significant(χ^(2)=4.945,P=0.027).The serum PSA levels after treatment in the two groups were significantly lower than before treatment(P<0.05),and the PSA level in the observation group after treatment was significantly lower than that in the control group,and the differences between the groups were statistically significant(P<0.05).After treatment,the quality of life scores of the two groups of patients were significantly improved than before,and the differences between the groups were statistically significant(P<0.05).Conclusions Abbitron combined with docetaxel in patients with mCRPC can improve the treatment effect,which is worthy of popularization and application.